DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Latva-Rasku A, Honka M-J, Kullberg J. et al.
The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients.
Diabetes Care 2019;
42 (05) 931-937
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.